Exit Centocor, Enter Fujirebio
Centocor's sale of its oncology diagnostics business to Fujirebio Inc. of Japan marks the end of an era for Centocor and the beginning of a new expansionist strategy at Fujirebio. Centocor wants to concentrate its resources on its flourishing pharmaceuticals business, while Fujirebio is eager to expand its diagnostics business globally.
You may also be interested in...
The possibility, which seems driven by the culture of the times, may be legally possible, but experts raised many practical concerns.
After concerns from the medtech industry that a 2017 final rule requires sponsors with knowledge of off-label use of their product to add it to their label, the US FDA is proposing to delete the confusing text.
If President Donald Trump appoints, and the Senate approves, a new conservative justice for the Supreme Court to replace Ruth Bader Ginsburg, Affordable Care Act coverage could disappear. Two legal experts weigh in on this and other legal issues that could touch the medical device industry.